Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology
暂无分享,去创建一个
Kazuhiko Yanai | Nobuyuki Okamura | Takeo Yoshikawa | Hiroyuki Arai | Ryuichi Harada | Ren Iwata | Shozo Furumoto | Makoto Higuchi | H. Arai | M. Higuchi | N. Okamura | T. Yoshikawa | S. Furumoto | R. Iwata | K. Yanai | Y. Kudo | R. Harada | M. Maruyama | T. Tago | Masahiro Maruyama | Yukitsuka Kudo | Tetsuro Tago
[1] B. Långström,et al. The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.
[2] James Robert Brašić,et al. An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients , 2013, Molecular Imaging and Biology.
[3] Seong Jin Cho,et al. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease , 2008, NeuroImage.
[4] Stefan Platzer,et al. Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease , 2012, PloS one.
[5] H. Arai,et al. Recent advances in the development of amyloid imaging agents. , 2007, Current topics in medicinal chemistry.
[6] Paul Maruff,et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.
[7] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[8] C. Rowe,et al. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. , 2009, European journal of pharmacology.
[9] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[10] C. Rowe,et al. In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.
[11] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[12] N. Cairns,et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia , 2010, Neurology.
[13] S. DeKosky,et al. Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.
[14] W. Klunk,et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.
[15] C. Masters,et al. The challenges of tau imaging , 2012 .
[16] Kazuhiko Yanai,et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. , 2011, Brain : a journal of neurology.
[17] G. Small,et al. Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.
[18] Kazuhiko Yanai,et al. 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients , 2007, Journal of Nuclear Medicine.
[19] F. Gallyas,et al. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. , 1971, Acta morphologica Academiae Scientiarum Hungaricae.
[20] G. Small,et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[21] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[22] Tetsuya Suhara,et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.
[23] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[24] H. Arai,et al. Quinoline and Benzimidazole Derivatives: Candidate Probes for In Vivo Imaging of Tau Pathology in Alzheimer's Disease , 2005, The Journal of Neuroscience.
[25] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[26] H. Braak,et al. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads , 2004, Acta Neuropathologica.
[27] V. Libri,et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.
[28] H. Braak,et al. Sequence of Aβ‐Protein Deposition in the Human Medial Temporal Lobe , 2000 .
[29] V. Libri,et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies , 2009, Journal of neurochemistry.
[30] H. Braak,et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. , 2000, Journal of neuropathology and experimental neurology.
[31] William E. Klunk,et al. The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component , 2003, The Journal of Neuroscience.
[32] E. Mandelkow,et al. Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. , 2004, Biochemistry.
[33] E. Mandelkow,et al. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. , 2006, Biochemistry.